AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
MarketBeat
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.
Rob Michael, AbbVie’s chairman and chief executive officer,
NYSE:ABBV